BUSINESS3 years ago
Phase 3 DETERMINE study of Lenabasum for Dermatomyositis did not Meet its Primary Endpoint, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) Reports
Throughout its existence, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has worked so hard in the development of innovative medicines that target inflammation, fibrosis, metabolism, and immuno-oncology....
